Fragile x syndrome
Drug research and approvals for fragile x syndrome: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 15 studies of fragile x syndrome are recruiting on ClinicalTrials.gov, Health Canada has authorized 6 drug trials for it since 2013, and FDA has 0 approved and 29 open orphan designations naming it.
- Recruiting worldwide: 15
- Trials authorized in Canada: 6
- FDA orphan approvals: 0
- EU medicines: 0
- Safety, Tolerability, and Preliminary Effectiveness of CTH120 in Fragile X SyndromeNCT07654114 · Phase 2 · Connecta Therapeutics, S.L. · starts May 21, 2026
- Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal…NCT07493096 · Not reported · Healing Hope International · starts Mar 1, 2026
- The Neurocognitive Bases of Trust in Intellectual DisabilityNCT07434037 · Not reported · Hospices Civils de Lyon · starts Jul 17, 2026
- Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)NCT07209462 · Phase 2 · Mirum Pharmaceuticals, Inc. · starts Nov 22, 2025
- Optical Imaging in X-linked Disorders.NCT06868979 · Not applicable · Hospices Civils de Lyon · starts Mar 30, 2026
- Physical Activity and Community EmPOWERment ProjectNCT06740162 · Not applicable · University of North Carolina, Chapel Hill · starts Jan 10, 2025
- Group CBT in Adolescents With Fragile X Syndrome and in Adolescents With Autism Spectrum DisorderNCT06677866 · Not applicable · Bambino Gesù Hospital and Research Institute · starts Sep 1, 2022
- Tracking Early Emergence of Sound Perception Impairments in FXS With Multimodal fNIRS/EEG- InfantNCT06560242 · Not applicable · Children's Hospital Medical Center, Cincinnati · starts Oct 31, 2022
- Effect of CANnabidiol on Anxiety and GABAergic Function in Individuals With Fragile-X SyndromeNCT06261502 · Phase 2 · Université de Sherbrooke · starts Sep 1, 2025
Phase 3 3
- ArbaclofenGABA-B receptor agonist
- ZatolmilastPhosphodiesterase 4D inhibitor
- CannabidiolCannabinoid CB1 receptor negative allosteric modulator
Phase 2 12 of 20
- MavoglurantMetabotropic glutamate receptor 5 antagonist
- MetforminMitochondrial complex I (NADH dehydrogenase) inhibitor
- AcamprosateGlutamate [NMDA] receptor antagonist
- BasimglurantMetabotropic glutamate receptor 5 modulator
- GaboxadolGamma-aminobutyric acid receptor subunit alpha-4/beta3/delta agonist
- BaclofenGABA-B receptor agonist
- DonepezilAcetylcholinesterase inhibitor
- LovastatinHMG-CoA reductase inhibitor
- MinocyclineBacterial 70S ribosome inhibitor
- STX107Metabotropic glutamate receptor 5 negative allosteric modulator
- AripiprazoleDopamine D2 receptor partial agonist
- OxytocinOxytocin receptor agonist
Phase 1 or earlier 3
- FlumazenilGABA-A receptor; anion channel allosteric antagonist
- AZD7325GABA receptor alpha-2 subunit positive allosteric modulator
- Fenobam
How its trials ended
102 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 24 whose ending is known, 33% met their primary endpoint, 21% missed it and 46% stopped early.
- Completed, result not reported4241%
- Ongoing2827%
- Stopped: other or unclear99%
- Met its primary endpoint88%
- Status unknown88%
- Missed its primary endpoint55%
- Stopped: lack of efficacy11%
- Stopped: enrollment or feasibility11%
| Oct 3, 2023 | Effect of cannabidiol on anxiety and gabaergic function in individuals with fragile-x syndrome (CANAX)Cannabidiol | Dr Francois Corbin | Pending |
| Dec 21, 2022 | An open-label investigation of the effects of sub-perceptual repeat dosing of psilocybin on the behavioural and cognitive symptoms of fragile x syndrome in…Psilocybin | Nova Mentis Life Science Corp | Closed |
| Mar 27, 2020 | Effect of cbd on the gabaergic system in patients with fragile x syndromeCannabidiol | Dr Francois Corbin | Pending |
| Nov 29, 2018 | A randomized, double-blind, placebo-controlled, multiple-center, efficacy and safety study of ZYN002 administered as a transdermal gel to children and…ZYN002 (cannabidiol) | Zynerba Pharmaceuticals | Pending |
| Oct 24, 2018 | A double-blind, placebo-controlled trial of metformin in individuals with fragile x syndrome (fxsMetformin | Governors of The University of Alberta | Ongoing |
| Jun 22, 2018 | Open study to evaluate the efficacy and safety of metformin in individuals with fragile x syndromeMetformin | Dr Artuela Caku | Ongoing |
| Nov 19, 2025 | Alkanoylamine derivative selective modulator of a Class A G…Treatment of fragile X syndrome (FXS) | GEXVal Inc. | Designated |
| Feb 28, 2025 | 3-Chloro-4-fluorophenyl-[4-fluoro-4-[[(5-methylpyrimidin-2-y…Treatment of Fragile X syndrome | Neurolixis, Inc. | Designated |
| Nov 19, 2024 | Small molecule modulator of large conductance,…Treatment of fragile X syndrome | Servier Pharmaceuticals LLC | Designated |
| May 14, 2024 | (R) 3-(5-Dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1-…Treatment of fragile X syndrome | Spinogenix, Inc. | Designated |
| Nov 3, 2022 | BlarcamesineTreatment of Fragile X syndrome | Anavex Life Sciences Corp. | Designated |
| Oct 24, 2022 | Lisuride MaleateTreatment of Fragile X Syndrome. | NeuroVenti Inc. | Designated |
| Jun 16, 2022 | Replication-incompetent adeno-associated virus serotype 9…Treatment of Fragile X Syndrome | Cincinnati Children's Hospital | Designated |
| Jun 15, 2022 | IbudilastTreatment of Fragile X syndrome | Healx Limited | Designated |
| May 26, 2022 | 4-(3-cyano-6-ethoxyquinolin-2-yl)-N-…Treatment of Fragile X syndrome (FXS) | Neuronascent, Inc. | Designated |
| Oct 25, 2021 | PsilocybinTreatment of Fragile X Syndrome | Nova Mentis Life Science Corp. | Designated |
| May 10, 2021 | SulindacTreatment of Fragile X syndrome | Healx Limited | Designated |
| Mar 28, 2019 | Alpha tocopherol and ascorbic acidTreatment of Fragile X syndrome | GenCo Pharmaceuticals LLC | Designated |
| Mar 26, 2018 | ZatolmilastTreatment of Fragile X Syndrome | Tetra Discovery Partners, Inc. | Designated |
| Oct 3, 2017 | GaboxadolTreatment of Fragile X syndrome | Healx Limited | Designated |
| Jun 12, 2017 | 5,5-dimethyl-3-[2-(7-methylspiro[2H-benzofuran-3,1'-cyclopro…Treatment of fragile X syndrome | Autifony Therapeutics Limited | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA